Rhelion unit Filament Health ships psilocybin candidate PEX010 to Australia for University of Melbourne trial

PUBT · 1d ago
Rhelion unit Filament Health ships psilocybin candidate PEX010 to Australia for University of Melbourne trial
  • Rhelion’s wholly owned Filament Health shipped botanical psilocybin candidate PEX010 from Canada to Australia for a University of Melbourne trial.
  • PSI-PHY will test psilocybin-assisted physiotherapy in adults with refractory motor functional neurological disorder at Austin Health in Melbourne.
  • Filament will supply standardized PEX010 doses of 1 mg, 5 mg, 25 mg; 0.5 mg expected to follow.
  • Rhelion acquired Filament on April 30, 2026, adding 76 issued patents across 15 patent families plus lead asset PEX010.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609080752NEWSFILECNPR____20260908_313338_1) on September 08, 2026, and is solely responsible for the information contained therein.